Coronavirus-19, monocyte/macrophage glycolysis and inhibition by melatonin
Abstract: Two highly relevant studies related to SARS-CoV-2 and coronavirus disease (COVID-19) and supporting the use of melatonin to prevent and treat this serious infection were published recently. Campos-Codo and colleagues [1] documented experimentally their claim that drugs which specifica...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Inglés |
| Publicado: |
Wright Academia
2022
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/13642 |
| Aporte de: |
| Sumario: | Abstract: Two highly relevant studies related to SARS-CoV-2
and coronavirus disease (COVID-19) and supporting
the use of melatonin to prevent and treat this serious
infection were published recently. Campos-Codo and
colleagues [1] documented experimentally their claim
that drugs which specifically target hypoxia inducible
factor-1α (HIF-1α) would likely have great therapeutic
value in treating COVID-19. The second report is a retrospective analysis based on the clinical experience at the
Columbia University Irving Medical Center with the use
of drugs to treat respiratory distress in COVID-19-infected patients who required endotracheal intubation [2].
Hyperinflammatory monocytes/macrophages accumulate in abundance in the lower respiratory tract
where they play a key role in determining the severity
of SARS-CoV-2 infections. Campos-Codo, et al. [1] found
that monocytes/macrophages infected with the SARSCoV-2 virus reprogram their metabolism from the conventional mitochondrial oxidative phosphorylation (OXPHOS) to the (usually) pathological cytosolic glycolysis.
This so-called Warburg-type metabolism is aided by the
inadequately controlled elevated blood glucose levels
of diabetic patients, which enhances cellular glycolysis,
viral replication and hastens development of a severe
respiratory infection resulting from the elevated cytokine release (“cytokine storm”). |
|---|